Offers Invited
Overview
An opportunity has arisen to acquire the business and assets of Advanced Oncotherapy PLC, a pioneering UK-based company active in the field of proton particle therapy. This advanced radiation-based approach to cancer treatment offers superior precision and fewer side effects compared to X-ray machines.
Established in 2006, and with technology initially nurtured at CERN, the company has designed a system (“LIGHT”) that provides the most precise and fastest proton beam for cancer treatment while offering significant cost savings for payers.
Due to LIGHT’s modularity, which allows for easier and cheaper installation into existing buildings, the equipment can be leased, accelerating market adoption and replicating the success of other medical equipment like MRI scanners. This results in significantly reduced upfront costs for any future operators.
In focus
LIGHT has been designed to deliver proton therapy, a more targeted radiation than X-rays, at a price closer to conventional radiation treatments.
The innovative technology promises better quality treatment with pinpoint accuracy compared to existing technologies.
The company has achieved a significant milestone by generating a high-energy proton beam, enabling LIGHT to treat tumours at depths of up to 32 cm and considerably de-risking the business plan. Following this achievement, the company will be integrating the linear accelerator with the equipment in the treatment room (such as the patient couch or the scanner used to locate the tumour), calibrating the imaging equipment, and obtaining regulatory approvals.
The technology aims to create synergies with other approaches, such as immunotherapy, and has the potential to treat non-cancerous disorders.
The company is currently installing a linear system into a Grade II listed townhouse in central London with construction costs of £10 million, compared to UCLH’s circular system, which cost approximately £190 million.
Initial expression of interest in relation to the business and assets by 5:00pm on 12 June 2024. FRP reserve the right to vary this timetable.
Should you wish to obtain access to the data room on this opportunity please contact the below Hilco representatives to receive an NDA. This will be issued by FRP, the Company’s administrators.
No warranties, express or implied, are provided in relation to any information or statements made in connection to this opportunity. The information contained herein, and within the project dataroom, has not been verified by Hilco and prospective purchasers must undertake their own due diligence to satisfy themselves as to the accuracy of all such information and any statements made. Hilco’s full Terms and Conditions apply. Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets.
Managing Director
London Office
